As of May 29, 2025, Pharma Mar SA (PHM.MC) reports a Forward P/E of 30.27.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Pharma Mar SA's Forward P/E to Peers
To better understand Pharma Mar SA's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Pharma Mar SA (PHM.MC) | 30.27 |
| Relief Therapeutics Holding SA (RLF.SW) | 2910.89 |
| Bioventix PLC (BVXP.L) | 1858.44 |
| Oryzon Genomics SA (ORY.MC) | 150.74 |
| Zealand Pharma A/S (ZEAL.CO) | 60.91 |
| Innate Pharma SA (IPH.PA) | 21.86 |
Compared to its competitors, Pharma Mar SA's Forward P/E is about average compared to peers, indicating growth expectations in line with industry peers.